Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to $364.8 million.

  • Centessa Pharmaceuticals' Cash from Financing Activities fell 98.60% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 96.99%. This contributed to the annual value of $364.8 million for FY2024, which is 1627.29% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Cash from Financing Activities of $364.8 million as of FY2024, which was up 1,627.29% from $21.1 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Cash from Financing Activities peaked at $660.1 million during FY2021, and registered a low of $457,000 during FY2022.
  • In the last 3 years, Centessa Pharmaceuticals' Cash from Financing Activities had a median value of $21.1 million in 2023 and averaged $128.8 million.
  • In the last 5 years, Centessa Pharmaceuticals' Cash from Financing Activities skyrocketed by 48,368.94% in 2021 and then plummeted by 99.93% in 2022.
  • Over the past 5 years, Centessa Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $1.4 million in 2020, then spiked by 48,368.94% to $660.1 million in 2021, then crashed by 99.93% to $457,000 in 2022, then soared by 4,520.79% to $21.1 million in 2023, then spiked by 1,627.29% to $364.8 million in 2024.